根治性前列腺癌低分割放疗的研究进展

doi:10.3760/cma.j.cn113030-20211007-00390

Abstract
Figure/Table
References(48)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Radiotherapy is one of the important treatment strategies for localized prostate cancer. Conventional fractionated external beam radiotherapy is the standard dose-fraction regimen of radical radiotherapy for localized prostate cancer. In recent years, hypofractionated radiotherapy technique has been developed rapidly. The moderately hypofractionated radiotherapy has been considered as an alternative to conventional fractionated radiotherapy in conditional institutions. Increasing evidence has been obtained in the application of ultra-hypofractionated radiotherapy (also known as stereotactic body radiotherapy, SBRT) in patients with low-and intermediate-risk prostate cancer. However, the efficacy and safety of SBRT for high-risk prostate cancer have not been fully demonstrated. In this review, research progressess on the efficacy and safety of radical hypofractionated radiotherapy and the techniques of SBRT for prostate cancer were summarized.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Fang
	Wang Xin

Key words： Prostate neoplasm Hypofractionated radiotherapy Research progress

Received: 07 October 2021

Fund:Surface project of National Natural Science Foundation of China (82073338), Sichuan Science and Technology Support Project (2021YFSY0039);The 1-3-5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University (2020HXFH002);The 1-3-5 Project for Disciplines of Excellence, West China Hospital, Sichuan University(ZYJC21059)

Corresponding Authors: Wang Xin, Email:wangxin213@sina.com

Cite this article:

Wang Fang,Wang Xin. Research progress on radical hypofractionated radiotherapy for prostate cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(1): 102-107.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20211007-00390 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I1/102

[1] World Health Organization. Cancer fact sheets[EB/OL][2020-12-1].https://gco.iarc.fr/today/fact-sheets-cancers.
[2] TAITT HE. Global trends and prostate cancer:a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location[J]. Am J Mens Health, 2018, 12(6):1807-1823. DOI:10.1177/1557988318798279.
[3] EIFLER JB, FENG Z, LIN BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011[J]. BJU Int, 2013, 111(1):22-29. DOI:10.1111/j.1464-410X.2012.11324.x.
[4] ABDOLLAH F, COZZARINI C, SUN M, et al. Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection[J]. Radiother Oncol, 2013, 109(2):211-216. DOI:10.1016/j.radonc.2013.05.029.
[5] 中国医促会泌尿健康促进分会,中国研究型医院学会泌尿外科学专业委员会. 前列腺癌放射治疗安全共识[J]. 现代泌尿外科杂志,2019, 24(5):336-346. DOI:10.3969/j.issn.1009-8291.2019.05.003.
Urological Health Promotion Branch of China Medical Promotion Association, Urological Surgery Professional Committee of Chinese Research Hospital Association. Consensus on the safety of radiotherapy for prostate cancer[J]. J Mod Urol, 2019, 24(5):336-346. DOI:10.3969/j.issn.1009-8291.2019.05.003.
[6] COSSET JM, CHARGARI C, CRÉHANGE G. Which alpha/beta ratio for prostate cancer in 2019?[J]. Cancer Radiother, 2019, 23(4):342-345. DOI:10.1016/j.canrad.2019.01.004.
[7] YEOH EE, BOTTEN RJ, BUTTERS J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma:final results of phase Ⅲ randomized trial[J]. Int J Radiat Oncol Biol Phys, 2011, 81(5):1271-1278. DOI:10.1016/j.ijrobp.2010.07.1984.
[8] LEE WR, DIGNAM JJ, AMIN MB, et al. Randomized phase Ⅲ noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer[J]. J Clin Oncol, 2016, 34(20):2325-2332. DOI:10.1200/JCO.2016.67.0448.
[9] POLLACK A, WALKER G, HORWITZ EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer[J]. J Clin Oncol, 2013, 31(31):3860-3868. DOI:10.1200/JCO.2013.51.1972.
[10] NAISMITH O, MAYLES H, BIDMEAD M, et al. Radiotherapy quality assurance for the CHHiP trial:conventional versus hypofractionated high-dose intensity-modulated radiotherapy in prostate cancer[J]. Clin Oncol (R Coll Radiol), 2019, 31(9):611-620. DOI:10.1016/j.clon.2019.05.009.
[11] DEARNALEY D, SYNDIKUS I, MOSSOP H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer:5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial[J]. Lancet Oncol, 2016, 17(8):1047-1060. DOI:10.1016/S1470-2045(16)30102-4.
[12] WILSON JM, DEARNALEY DP, SYNDIKUS I, et al. The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population:a subgroup analysis of the CHHiP trial[J]. Int J Radiat Oncol Biol Phys, 2018, 100(5):1179-1189. DOI:10.1016/j.ijrobp.2018.01.016.
[13] DATTA NR, STUTZ E, ROGERS S, et al. Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer:a systematic review and meta-analysis along with therapeutic implications[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3):573-589. DOI:10.1016/j.ijrobp.2017.07.021.
[14] ZAORSKY NG, OHRI N, SHOWALTER TN, et al. Systematic review of hypofractionated radiation therapy for prostate cancer[J]. Cancer Treat Rev, 2013, 39(7):728-736. DOI:10.1016/j.ctrv.2013.01.008.
[15] KOONTZ BF, BOSSI A, COZZARINI C, et al. A systematic review of hypofractionation for primary management of prostate cancer[J]. Eur Urol, 2015, 68(4):683-691. DOI:10.1016/j.eururo.2014.08.009.
[16] LUKKA H, HAYTER C, JULIAN JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer[J]. J Clin Oncol, 2005, 23(25):6132-6138. DOI:10.1200/JCO.2005.06.153.
[17] STEPHENSON AJ. Is the Phoenix definition superior to ASTRO for predicting clinical outcomes in prostate cancer?[J]. Nat Clin Pract Urol, 2008, 5(7):356-357. DOI:10.1038/ncpuro1126.
[18] INCROCCI L, WORTEL R C, ALEMAYEHU W G, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO):final efficacy results from a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2016, 17(8):1061-1069. DOI:10.1016/S1470-2045(16)30070-5.
[19] ARCANGELI G, FOWLER J, GOMELLINI S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(4):1013-1021. DOI:10.1016/j.ijrobp.2009.12.045.
[20] ALUWINI S, POS F, SCHIMMEL E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO):acute toxicity results from a randomised non-inferiority phase 3 trial[J]. Lancet Oncol, 2015, 16(3):274-283. DOI:10.1016/S1470-2045(14)70482-6.
[21] ALUWINI S, POS F, SCHIMMEL E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO):late toxicity results from a randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2016, 17(4):464-474. DOI:10.1016/S1470-2045(15)00567-7.
[22] WORTEL RC, POS FJ, HEEMSBERGEN WD, et al. Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer:results from the randomized phase Ⅲ HYPRO trial[J]. J Sex Med, 2016, 13(11):1695-1703. DOI:10.1016/j.jsxm.2016.08.012.
[23] MURTHY V, MAITRE P, BHATIA J, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT):a randomised trial[J]. Radiother Oncol, 2020, 145:71-80. DOI:10.1016/j.radonc.2019.12.006.
[24] ZELEFSKY MJ, KOLLMEIER M, MCBRIDE S, et al. Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 104(1):42-49. DOI:10.1016/j.ijrobp.2018.12.045.
[25] KING CR, BROOKS JD, GILL H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2):877-882. DOI:10.1016/j.ijrobp.2010.11.054.
[26] MEIER RM, BLOCH DA, COTRUTZ C, et al. Multicenter trial of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer:survival and toxicity endpoints[J]. Int J Radiat Oncol Biol Phys, 2018, 102(2):296-303. DOI:10.1016/j.ijrobp.2018.05.040.
[27] MADSEN BL, HSI RA, PHAM HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease:first clinical trial results[J]. Int J Radiat Oncol Biol Phys, 2007, 67(4):1099-1105. DOI:10.1016/j.ijrobp.2006.10.050.
[28] BOYER MJ, PAPAGIKOS MA, KITELEY R, et al. Toxicity and quality of life report of a phase Ⅱ study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer[J]. Radiat Oncol, 2017, 12(1):14. DOI:10.1186/s13014-016-0758-8.
[29] BRAND DH, TREE AC, OSTLER P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial[J]. Lancet Oncol, 2019, 20(11):1531-1543. DOI:10.1016/S1470-2045(19)30569-8.
[30] WIDMARK A, GUNNLAUGSSON A, BECKMAN L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer:5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial[J]. Lancet, 2019, 394(10196):385-395. DOI:10.1016/S0140-6736(19)31131-6.
[31] ROYCE TJ, MAVROIDIS P, WANG K, et al. Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2021, 110(1):227-236. DOI:10.1016/j.ijrobp.2020.08.014.
[32] JACKSON WC, SILVA J, HARTMAN HE, et al. Stereotactic body radiation therapy for localized prostate cancer:a systematic review and meta-analysis of over 6,000 patients treated on prospective studies[J]. Int J Radiat Oncol Biol Phys, 2019, 104(4):778-789. DOI:10.1016/j.ijrobp.2019.03.051.
[33] MURTHY V, GUPTA M, MULYE G, et al. Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer[J]. Clin Oncol (R Coll Radiol), 2018, 30(7):442-447. DOI:10.1016/j.clon.2018.03.004.
[34] MUSUNURU HB, D′ALIMONTE L, DAVIDSON M, et al. Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN):early toxicity and quality of life[J]. Int J Radiat Oncol Biol Phys, 2018, 102(5):1438-1447. DOI:10.1016/j.ijrobp.2018.07.2005.
[35] BAUMAN G, FERGUSON M, LOCK M, et al. A phase 1/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 92(4):856-862. DOI:10.1016/j.ijrobp.2015.02.046.
[36] KOSKELA K, PALMGREN JE, HEIKKILÃJ, et al. Hypofractionated stereotactic body radiotherapy for localized prostate cancer-first Nordic clinical experience[J]. Acta Oncol, 2017, 56(7):978-983. DOI:10.1080/0284186X.2017.1288923.
[37] CELLINI N, MORGANTI AG, MATTIUCCI GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy:implications for conformal therapy planning[J]. Int J Radiat Oncol Biol Phys, 2002, 53(3):595-599. DOI:10.1016/s0360-3016(02)02795-5.
[38] DRAULANS C, VAN DER HEIDE UA, HAUSTERMANS K, et al. Primary endpoint analysis of the multicentre phase Ⅱ hypo-FLAME trial for intermediate and high risk prostate cancer[J]. Radiother Oncol, 2020, 147:92-98. DOI:10.1016/j.radonc.2020.03.015.
[39] BROCK KK. Adaptive radiotherapy:moving into the future[J]. Semin Radiat Oncol, 2019, 29(3):181-184. DOI:10.1016/j.semradonc.2019.02.011.
[40] FISCHER-VALUCK BW, CHUNDURY A, GAY H, et al. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer:impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall[J]. Pract Radiat Oncol, 2017, 7(3):195-202. DOI:10.1016/j.prro.2016.10.004.
[41] CUCCIA F, MAZZOLA R, NICOSIA L, et al. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy[J]. Radiat Oncol, 2020, 15(1):178. DOI:10.1186/s13014-020-01622-3.
[42] HWANG ME, MAYEDA M, LIZ M, et al. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer:toxicity profile and early oncologic outcomes[J]. Radiat Oncol, 2019, 14(1):136. DOI:10.1186/s13014-019-1346-5.
[43] MARIADOS N, SYLVESTER J, SHAH D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial:dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2015, 92(5):971-977. DOI:10.1016/j.ijrobp.2015.04.030.
[44] SEYMOUR ZA, HAMSTRA DA, DAIGNAULT-NEWTON S, et al. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer:a pooled prospective evaluation of bowel-associated quality of life[J]. BJU Int, 2020, 126(3):367-372. DOI:10.1111/bju.15097.
[45] XIANG HF, LU HM, EFSTATHIOU JA, et al. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer[J]. J Appl Clin Med Phys, 2017, 18(3):37-43. DOI:10.1002/acm2.12063.
[46] GRECO C, PARES O, PIMENTEL N, et al. Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy:results from a phase Ⅱ study[J]. Radiother Oncol, 2020, 146:21-28. DOI:10.1016/j.radonc.2020.01.029.
[47] JONES RT, HASSAN REZAEIAN N, DESAI NB, et al. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs. injectable spacer gel in stereotactic body radiation therapy for prostate cancer:lessons learned from prospective trials[J]. Med Dosim, 2017, 42(4):341-347. DOI:10.1016/j.meddos.2017.07.002.
[48] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN prostate cancer clinical practice guidelines in oncology (version 1 2022)[EB/OL][2021-09-10]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459.